Zonisamide: Aspects in neuroprotection

Experimental Neurology

Volumn 224, Issue 2, 2010, Pages 336-339

  Rösler, Thomas W ^a   Arias Carrión, Oscar ^a   Höglinger, Günter U ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

Dopaminergic system; MAO B; Neuroprotection; Parkinson's disease; Zonisamide

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 NITROPROPIONIC ACID; 3,4 DIHYDROXYPHENYLACETIC ACID; ACETYLCHOLINESTERASE; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BICUCULLINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE INHIBITOR; PLACEBO; ROTENONE; SELEGILINE; TYROSINE 3 MONOOXYGENASE; ZONISAMIDE;

ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; BRAIN INFARCTION; CLINICAL TRIAL; DOPAMINERGIC SYSTEM; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TREATMENT FAILURE; ENZYME INHIBITION; EPILEPSY; EXCITATORY POSTSYNAPTIC POTENTIAL; GABAERGIC SYSTEM; HUMAN; HUNTINGTON CHOREA; IC 50; NERVE DEGENERATION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NOTE; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; ANTICONVULSANTS; ANTIPARKINSON AGENTS; HUMANS; ISOXAZOLES; NEURONS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 77954656844     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.04.017     Document Type: Note

References (34)

1. Asanuma M., Miyazaki I., Diaz-Corrales F.J., Miyoshi K., Ogawa N., Murata M. Preventing effects of a novel anti-parkinsonian agent zonisamide on dopamine quinone formation. Neurosci. Res. 2008, 60:106-113.
2. Atli A., Dogra S. Zonisamide in the treatment of painful diabetic neuropathy: a randomized, double-blind, placebo-controlled pilot study. Pain Med. 2005, 6:225-234.
3. Costa C., Tozzi A., Luchetti E., Siliquini S., Belcastro V., Tantucci M., Picconi B., Ientile R., Calabresi P., Pisani F. Electrophysiological actions of zonisamide on striatal neurons: selective neuroprotection against complex I mitochondrial dysfunction. Exp. Neurol. 2010, 221:217-224.
4. Drake M.E., Greathouse N.I., Renner J.B., Armentbright A.D. Open-label zonisamide for refractory migraine. Clin. Neuropharmacol. 2004, 27:278-280.
5. Fornai F., Chen K., Giorgi F.S., Gesi M., Alessandri M.G., Shih J.C. Striatal dopamine metabolism in monoamine oxidase B-deficient mice: a brain dialysis study. J. Neurochem. 1999, 73:2434-2440.
6. Frim D.M., Simpson J., Uhler T.A., Short M.P., Bossi S.R., Breakefield X.O., Isacson O. Striatal degeneration induced by mitochondrial blockade is prevented by biologically delivered NGF. J. Neurosci. Res. 1993, 35:452-458.
7. Gluck M.R., Santana L.A., Granson H., Yahr M.D. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. J. Neural Transm. 2004, 111:713-724.
8. Hauser R.A., Lew M.F., Hurtig H.I., Ondo W.G., Wojcieszek J., Fitzer-Attas C.J. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov. Disord. 2009, 24:564-573.
9. Hayakawa T., Higuchi Y., Nigami H., Hattori H. Zonisamide reduces hypoxic-ischemic brain damage in neonatal rats irrespective of its anticonvulsive effect. Eur. J. Pharmacol. 1994, 257:131-136.
10. Heikkila R.E., Manzino L., Cabbat F.S., Duvoisin R.C. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1, 2, 5, 6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 1984, 311:467-469.
11. Komatsu M., Okamura Y., Hiramatsu M. Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats. Neurosciences 1995, 21:23-29.
12. Komatsu M., Hiramatsu M., Willmore L.J. Zonisamide reduces the increase in 8-hydroxy-2'-deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats. Epilepsia 2000, 41:1091-1094.
13. Kothare S.V., Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin. Drug Metab. Toxicol. 2008, 4:493-506.
14. Lotharius J., O'Malley K.L. The parkinsonism-inducing drug 1-methyl-4-phenylpyridinium triggers intracellular dopamine oxidation. A novel mechanism of toxicity. J. Biol. Chem. 2000, 275:38581-38588.
15. McElroy S.L., Kotwal R., Guerdjikova A.I., Welge J.A., Nelson E.B., Lake K.A., D'Alessio D.A., Keck P.E., Hudson J.I. Zonisamide in the treatment of binge eating disorder with obesity: a randomized controlled trial. J. Clin. Psychiatry 2006, 67:1897-1906.
16. Minato H., Kikuta C., Fujitani B., Masuda Y. Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-reperfusion in rats. Epilepsia 1997, 38:975-980.
17. Mori A., Noda Y., Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res. 1998, 30:153-158.
18. Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr. Pharm. Des. 2004, 10:687-693.
19. Murata M., Horiuchi E., Kanazawa I. Zonisamide has beneficial effects on Parkinson's disease patients. Neurosci. Res. 2001, 41:397-399.
20. Murata, M., Hasegawa, K., Kanazawa, I., The Japan Zonisamide on PD Study Group, 2007. Zonisamide improves motor function in Parkinson's disease. Neurology 68, 45-50.
21. Noda Y., Mori A., Packer L. Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-d-aspartate and buthionine sulfoximine in the rat hippocampus. Res. Commun. Mol. Pathol. Pharmacol. 1999, 105:23-33.
22. Okada M., Kaneko S., Hirano T., Mizuno K., Kondo T., Otani K., Fukushima Y. Effects of zonisamide on dopaminergic system. Epilepsy Res. 1995, 22:193-205.
23. Olanow C.W. Can we achieve neuroprotection with currently available anti-parkinsonian interventions?. Neurology 2009, 72:59-64.
24. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., Langston W., Melamed E., Poewe W., Stocchi F., Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N. Engl. J. Med. 2009, 361:1268-1278.
25. Owen A.J., Ijaz S., Miyashita H., Wishart T., Howlett W., Shuaib A. Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vivo microdialysis and behavioral study. Brain Res. 1997, 770:115-122.
26. Rock D.M., Macdonald R.L., Taylor C.P. Blockade of sustained repetitiveaction potentials in cultured spinal cord neurons by zonisamide (AD810, CI 912), a novel anticonvulsant. Epilepsy Res. 1989, 3:138-143.
27. Rodriguez-Oroz M.C., Jahanshahi M., Krack P., Litvan I., Macias R., Bezard E., Obeso J.A. Initial clinical manifestations of Parkinson's disease: features and pathophysiological mechanisms. Lancet Neurol. 2009, 8:1128-1139.
28. Santiago M., Granero L., Machado A., Cano J. Complex I inhibitor effect on the nigral and striatal release of dopamine in the presence and absence of nomifensine. Eur. J. Pharmacol. 1995, 280:251-256.
29. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. J. Neurosci. 2003, 23:10756-10764.
30. Sonsalla P.K., Wong L.Y., Winnik B., Buckley B. The antiepileptic drug zonisamide inhibits MAO-B and attenuates MPTP toxicity in mice: clinical relevance. Exp. Neurol. 2010, 221:329-334.
31. Uno H., Kurokawa M., Masuda Y., Nishimura H. Studies on 3-substituted 1, 2-benzisoxazole derivatives. 6. Syntheses of 3-(sulfamoylmethyl)-1, 2-benzisoxazole derivatives and their anticonvulsant activities. J. Med. Chem. 1979, 22:180-183.
32. Yamamura S., Ohoyama K., Nagase H., Okada M. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology 2009, 57:322-331.
33. Yano R., Yokoyama H., Kuroiwa H., Kato H., Araki T. A novel anti-Parkinsonian agent, zonisamide, attenuates MPTP-induced neurotoxicity in mice. J. Mol. Neurosci. 2009, 39:211-219.
34. Zhu G., Okada M., Murakami T., Kawata Y., Kamata A., Kaneko S. Interaction between carbamazepine, zonisamide and voltage-sensitive Ca2+ channel on acetylcholine release in rat frontal cortex. Epilepsy Res. 2002, 49:49-60.